Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Cardiovascular Medicine
Erschienen in: Current Treatment Options in Cardiovascular Medicine 2/2014

01.02.2014 | Heart Failure (W Tang, Section Editor)

Medical Management of Patients With Continuous-Flow Left Ventricular Assist Devices

verfasst von: Adam D. DeVore, MD, Robert J. Mentz, MD, Chetan B. Patel, MD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Opinion statement

The prevalence of patients living with advanced heart failure continues to rise. For a subset of these patients, continuous-flow left ventricular assist devices (LVADs) are a life-saving therapy. Given the efficacy and durability of contemporary LVAD devices, their use has increased exponentially in recent years. The medical management of patients with an LVAD is an area of expertise for advanced heart failure clinicians, but a general understanding of the initial approach to, and stabilization of, LVAD patients is an important skillset for many health care providers. The rapidly changing field of the medical management of LVAD patients is largely based on clinical experience and limited published data. In this manuscript, we integrate the available published data on the medical management of LVAD patients with the growing clinical experience.
Literatur
1.
2.
Go AS et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245.PubMedCrossRef
3.
Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;122(2):173–83.PubMedCrossRef
4.
Costanzo MR, Mills RM, Wynne J. Characteristics of “Stage D” heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). Am Heart J. 2008;155(2):339–47.PubMedCrossRef
5.
INTERMACS Quarterly Statistical Report. Centers for Medicare & Medicaid Services. 2013 1st Quarter. 2013, The data collection and analysis center University of Alabama at Birmingham.
6.•
Kirklin JK et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant. 2013;32(2):141-56. The most recent report from INTERMACS, a registry of patients receiving mechanical circulatory support. These annual reports provide valuable information on type of mechanical support utilized, adverse events, and survival ratesPubMedCrossRef
7.
Slaughter MS et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29(4 Suppl):S1–39.PubMedCrossRef
8.•
Feldman D et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157-87. Recently published guidelines by the International Society of Heart and Lung Transplantation (ISHLT) for patients treated with mechanical circulatory support. These are the most comprehensive treatment guidelines published to datePubMedCrossRef
9.
Patel C, Alexander K, Rogers J. Mechanical circulatory support for advanced heart failure. Curr Treat Options Cardiovasc Med. 2010;12(6):549–65.PubMedCrossRef
10.
Khazanie P, Rogers JG. Patient selection for left ventricular assist devices. Congest Heart Fail. 2011;17(5):227–34.PubMedCrossRef
11.
Radovancevic R et al. Plasma exchange before surgery for left ventricular assist device implantation. Artificial Organs. 2008;32(6):427–32.PubMedCrossRef
12.
Matthews JC et al. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51(22):2163–72.PubMedCentralPubMedCrossRef
13.
Kormos RL et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139(5):1316–24.PubMedCrossRef
14.
Fitzpatrick 3rd JR et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant. 2008;27(12):1286–92.PubMedCentralPubMedCrossRef
15.
Drakos SG et al. Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol. 2010;105(7):1030–5.PubMedCrossRef
16.
Grant ADM et al. Independent and incremental role of quantitative right ventricular evaluation for the prediction of right ventricular failure after left ventricular assist device implantation. J Am Coll Cardiol. 2012;60(6):521–8.PubMedCrossRef
17.
Fitzpatrick 3rd JR et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137(4):971–7.PubMedCentralPubMedCrossRef
18.
Piacentino III V et al. Impact of tricuspid valve regurgitation in patients treated with implantable left ventricular assist devices. Ann Thorac Surg. 2011;91(5):1342–7.PubMedCrossRef
19.
Hillis LD et al. ACCF/AHA Guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(24):e123–210.PubMedCrossRef
20.
Borgi J et al. Significance of postoperative acute renal failure after continuous-flow left ventricular assist device implantation. Ann Thorac Surg. 2013;95(1):163–9.PubMedCrossRef
21.
22.
23.
Slaughter MS et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant. 2010;29(6):616–24.PubMedCrossRef
24.
Mentz RJ et al. Dysphagia in the setting of left ventricular assist device hemolysis. ASAIO J. 2013;59(3):322–3.PubMedCrossRef
25.
Zierer A et al. Late-onset driveline infections: the Achilles’ heel of prolonged left ventricular assist device support. Ann Thorac Surg. 2007;84(2):515–20.PubMedCrossRef
26.
Wever-Pinzon O et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013;6(3):517–26.PubMedCrossRef
27.
Cowger J et al. The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail. 2010;3(6):668–74.PubMedCentralPubMedCrossRef
28.
Pak S-W et al. Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant. 2010;29(10):1172–6.PubMedCrossRef
29.
Aggarwal A et al. The development of aortic insufficiency in continuous-flow left ventricular assist device–supported patients. Ann Thorac Surg. 2013;95(2):493–8.PubMedCrossRef
30.•
Uriel N et al. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol. 2012;60(18):1764-75. The first rigorous study of an echocardiographic-based protocol to determine optimal LVAD speed settings and to evaluate for device thrombosisPubMedCentralPubMedCrossRef
31.
Miller LW et al. Use of a continuous-flow device in patients awaiting heart transplantation. New Engl J Med. 2007;357(9):885–96.PubMedCrossRef
32.•
Aaronson KD et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125(25):3191-200. Results from ADVANCE, a multicenter trial of the HeartWare HVAD in patients receiving an LVAD as a bridge to transplantation. The control arm for the study was a similar group of patients in INTERMACS. The results of this study led to the FDA approval of the HeartWare HVAD for this indication.PubMedCrossRef
33.
Ziv O et al. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol. 2005;45(9):1428–34.PubMedCrossRef
34.
Brenyo A et al. Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. J Cardiovasc Electrophysiol. 2012;23(5):515–20.PubMedCrossRef
35.
Bedi M et al. Ventricular arrhythmias during left ventricular assist device support. Am J Cardiol. 2007;99(8):1151–3.PubMedCrossRef
36.
Cantillon DJ et al. Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm. 2010;7(4):466–71.PubMedCrossRef
37.
Andersen M et al. Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). J Heart Lung Transplant. 2009;28(7):733–5.PubMedCrossRef
38.
Ambardekar AV et al. Implantable cardioverter-defibrillator shocks in patients with a left ventricular assist device. J Heart Lung Transplant. 2010;29(7):771–6.PubMedCrossRef
39.
Kühne M et al. Simultaneous use of implantable cardioverter-defibrillators and left ventricular assist devices in patients with severe heart failure. Am J Cardiol. 2010;105(3):378–82.PubMedCrossRef
40.
Oswald H et al. Implantable defibrillator therapy for ventricular tachyarrhythmia in left ventricular assist device patients. Eur J Heart Fail. 2010;12(6):593–9.PubMedCrossRef
41.
Refaat MM et al. Survival benefit of implantable cardioverter-defibrillators in left ventricular assist device-supported heart failure patients. J Card Fail. 2012;18(2):140–5.PubMedCentralPubMedCrossRef
42.
Garan AR et al. Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices. Need for primary prevention? J Am Coll Cardiol. 2013;61(25):2542–50.PubMedCrossRef
43.
Ambardekar AV et al. Effect of left ventricular assist device placement on preexisting implantable cardioverter-defibrillator leads. J Card Fail. 2010;16(4):327–31.PubMedCrossRef
44.•
Gordon RJ et al. Prospective, multicenter study of ventricular assist device infections. Circulation. 2013;127(6):691-702. Results from the Ventricular Assist Device Infection Study Group. This was a comprehensive, multicenter study of infections in patients with LVADsPubMedCrossRef
45.
O’Shea G, Teuteberg JJ, Severyn DA. Monitoring patients with continuous-flow ventricular assist devices outside of the intensive care unit: novel challenges to bedside nursing. Prog Transplant. 2013;23(1):39–46.PubMedCrossRef
46.
Yancy CW et al. ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013.
47.
Shah P et al. Lactate dehydrogenase is superior to serum free hemoglobin as a marker of pump thrombosis in left ventricular assist devices. J Heart Lung Transplant. 2013;32(4 Supplement):S37.CrossRef
48.
Goldstein DJ et al. Young patients with nonischemic cardiomyopathy have higher likelihood of left ventricular recovery during left ventricular assist device support. J Card Fail. 2012;18(5):392–5.PubMedCrossRef
49.
Birks EJ et al. Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart Failure. New Engl J Med. 2006;355(18):1873–84.PubMedCrossRef
50.
Birks EJ et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123(4):381–90.PubMedCrossRef
51.
Dandel M et al. Heart failure reversal by ventricular unloading in patients with chronic cardiomyopathy: criteria for weaning from ventricular assist devices. Eur Heart J. 2011;32(9):1148–60.PubMedCrossRef
52.
Estep JD et al. The role of echocardiography and other imaging modalities in patients with left ventricular assist devices. JACC Cardiovasc Imaging. 2010;3(10):1049–64.PubMedCrossRef
53.
Rasalingam R et al. Transthoracic echocardiographic assessment of continuous-flow left ventricular assist devices. J Am Soc Echocardiogr. 2011;24(2):135–48.PubMedCrossRef
54.
Estep JD et al. Imaging for ventricular function and myocardial recovery on nonpulsatile ventricular assist devices. Circulation. 2012;125(18):2265–77.PubMedCrossRef
55.
Jessup ML et al. 5 Risk for bleeding after MCSD implant: an analysis of 2358 patients in INTERMACS. J Heart Lung Transplant. 2011;30(4):S9.CrossRef
56.
Bonde P et al. 4 National trends in readmission(REA) rates following left ventricular assist device (LVAD) therapy. J Heart Lung Transplant. 2011;30(4):S9.CrossRef
57.
Suarez J et al. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail. 2011;4(6):779–84.PubMedCrossRef
58.
Lewis BS et al. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol. 1992;15(2):99–103.PubMedCrossRef
59.
Junquera F et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology. 2001;121(5):1073–9.PubMedCrossRef
60.
Junquera F et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol. 2007;102(2):254–60.PubMedCrossRef
61.
Dray X et al. Treatment of gastrointestinal angiodysplasia and unmet needs. Dig Liver Dis. 2011;43(7):515–22.PubMedCrossRef
62.
Uriel N et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56(15):1207–13.PubMedCrossRef
63.
Gordon SM et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg. 2001;72(3):725–30.PubMedCrossRef
64.
Simon D et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis. 2005;40(8):1108–15.PubMedCrossRef
65.
Topkara VK et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg. 2010;90(4):1270–7.PubMedCrossRef
66.
Hannan MM et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant. 2011;30(4):375–84.PubMedCrossRef
67.
Vollkron M et al. Suction events during left ventricular support and ventricular arrhythmias. J Heart Lung Transplant. 2007;26(8):819–25.PubMedCrossRef
68.
Cantillon DJ et al. Electrophysiologic characteristics and catheter ablation of ventricular tachyarrhythmias among patients with heart failure on ventricular assist device support. Heart Rhythm. 2012;9(6):859–64.PubMedCrossRef
69.
Dandamudi G et al. Endocardial catheter ablation of ventricular tachycardia in patients with ventricular assist devices. Heart Rhythm. 2007;4(9):1165–9.PubMedCrossRef
70.
Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91(6, Supplement 1):2–8.CrossRef
71.
Maury P et al. First experience of percutaneous radio-frequency ablation for atrial flutter and atrial fibrillation in a patient with HeartMate II left ventricular assist device. J Intervent Card Electrophysiol. 2010;29(1):63–7.CrossRef
72.
Slaughter MS et al. Advanced heart failure treated with continuous-flow left ventricular assist device. New Engl J Med. 2009;361(23):2241–51.PubMedCrossRef
73.
Rajagopal K et al. Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation. J Thorac Cardiovasc Surg. 2013;145(5):1373–9.PubMedCrossRef
74.
Wang TS et al. Valvular heart disease in patients supported with left ventricular assist devices. Circ Heart Fail. 2013.
75.
Grohmann J et al. Trans-catheter closure of the native aortic valve with an Amplatzer® Occluder to treat progressive aortic regurgitation after implantation of a left-ventricular assist device. Eur J Cardio Thorac Surg. 2011;39(6):e181–3.CrossRef
76.
Freed BH et al. Percutaneous transcatheter closure of the native aortic valve to treat de novo aortic insufficiency after implantation of a left ventricular assist device. JACC Cardiovasc Interv. 2012;5(3):358–9.PubMedCrossRef
77.
Russo MJ et al. Percutaneous transcatheter closure of the aortic valve to treat cardiogenic shock in a left ventricular assist device patient with severe aortic insufficiency. Ann Thorac Surg. 2012;94(3):985–8.PubMedCrossRef
78.
Parikh KS et al. Percutaneous transcatheter aortic valve closure successfully treats left ventricular assist device–associated aortic insufficiency and improves cardiac hemodynamics. JACC: Cardiovascular Interventions. 2013;6(1):84–9.PubMed
79.
Santini F et al. First successful management of aortic valve insufficiency associated with heartmate ii left ventricular assist device support by transfemoral corevalve implantation: the Columbus’s egg? JACC: Cardiovascular Interventions. 2012;5(1):114–5.PubMed
80.
D’Ancona G et al. TAVI for pure aortic valve insufficiency in a patient with a left ventricular assist device. Ann Thorac Surg. 2012;93(4):e89–91.PubMedCrossRef
81.
Holman WL et al. Durability of left ventricular assist devices: interagency registry for mechanically assisted circulatory support (INTERMACS) 2006 to 2011. J Thorac Cardiovasc Surg. 2013;146(2):437–441.e1.PubMedCrossRef
Metadaten
Titel
Medical Management of Patients With Continuous-Flow Left Ventricular Assist Devices
verfasst von
Adam D. DeVore, MD
Robert J. Mentz, MD
Chetan B. Patel, MD
Publikationsdatum
01.02.2014
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 2/2014
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-013-0283-0

Weitere Artikel der Ausgabe 2/2014

Current Treatment Options in Cardiovascular Medicine 2/2014 Zur Ausgabe

Heart Failure (W Tang, Section Editor)

Should We Target Obesity in Advanced Heart Failure?

Cerebrovascular Disease and Stroke (D Greer, Section Editor)

Intra-Arterial Treatment of Acute Ischemic Stroke: The Continued Evolution

Heart Failure (W Tang, Section Editor)

Sodium Restriction in Heart Failure: Benefit or Harm?

Cerebrovascular Disease and Stroke (D Greer, Section Editor)

Perioperative Stroke: Risk Assessment, Prevention and Treatment

Heart Failure (W Tang, Section Editor)

Use of Novel Oral Anticoagulants in Patients With Heart Failure

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise